C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Core Insights - C4 Therapeutics, Inc. has appointed Stephen Fawell, Ph.D. to its Board of Directors, while Malcolm Salter retires after nearly a decade of service [1][2] Company Developments - The appointment of Dr. Fawell is expected to leverage his extensive experience in drug discovery and development, particularly in oncology, to advance C4 Therapeutics' mission of developing degrader medicines [2] - Dr. Fawell has nearly 35 years of experience in drug discovery, having transitioned over 25 new drugs into clinical trials during his tenure at AstraZeneca [2] - C4 Therapeutics focuses on targeted protein degradation to create innovative medicines, utilizing its TORPEDO® platform to design small-molecule therapies for difficult-to-treat diseases [3] Leadership Transition - Andrew Hirsch, CEO of C4 Therapeutics, expressed gratitude towards Malcolm Salter for his contributions, which included helping the company become publicly traded and advancing several medicines into clinical development [2] - Dr. Fawell expressed enthusiasm about joining the Board and supporting the management team in advancing the company's portfolio towards pivotal milestones [2]